Calithera Biosciences, Inc. (CALA) financial statements (2022 and earlier)

Company profile

Business Address 343 OYSTER POINT BLVD #200
SOUTH SAN FRANCISCO, CA 94080
State of Incorp. DE
Fiscal Year End December 31
SIC 2834 - Pharmaceutical Preparations (benchmarking)
More info Complete financial analysis Financial benchmarking

Balance sheet (Statement of financial position) ($ in thousands)

12/31/2021
Q4
9/30/2021
Q3
6/30/2021
Q2
3/31/2021
Q1
12/31/2020
Q4
9/30/2020
Q3
6/30/2020
Q2
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments59,53784,49392,205101,351107,146120,582114,895
Cash and cash equivalents59,53784,49392,205101,351107,146120,582114,895
Receivables 12121,0281,541466923
Other undisclosed current assets1,9151,8291,7764,13010,01618,98840,734
Total current assets:61,45286,33493,993106,509118,703140,036156,552
Noncurrent Assets
Operating lease, right-of-use asset2,4782,7453,0063,2615,7546,1446,526
Property, plant and equipment556622544617690744808
Restricted cash and investments270270270270440440440
Other noncurrent assets  46  344601
Total noncurrent assets:3,3043,6373,8664,1486,8847,6728,375
TOTAL ASSETS:64,75689,97197,859110,657125,587147,708164,927
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities7,5467,7075,5785,0498,5888,7665,253
Accounts payable3,6502,9711,5341,6361,9942,636672
Accrued liabilities6138627618781,4521,476921
Employee-related liabilities3,2833,8743,2832,5355,1424,6543,660
Other undisclosed current liabilities6,4605,8236,9008,7439,81311,03510,599
Total current liabilities:14,00613,53012,47813,79218,40119,80115,852
Noncurrent Liabilities
Long-term debt and lease obligation1,6662,0222,3682,7074,8155,3115,791
Operating lease, liability1,6662,0222,3682,7074,8155,3115,791
Other undisclosed noncurrent liabilities(1,666)(2,022)(2,368)(2,707)(4,815)(5,311)(5,791)
Total noncurrent liabilities: 2,0222,3682,707 5,3115,791
Total liabilities:15,67215,55214,84616,49923,21625,11221,643
Temporary equity, carrying amount40,702      
Stockholders' equity
Stockholders' equity attributable to parent8,38274,41983,01394,158102,371122,596143,284
Common stock8777777
Additional paid in capital499,700496,528493,950490,784478,599476,215474,098
Accumulated other comprehensive income    346117
Accumulated deficit(491,326)(422,116)(410,944)(396,633)(376,238)(353,672)(330,938)
Total stockholders' equity:8,38274,41983,01394,158102,371122,596143,284
TOTAL LIABILITIES AND EQUITY:64,75689,97197,859110,657125,587147,708164,927

Income statement (P&L) ($ in thousands)

12/31/2021
Q4
9/30/2021
Q3
6/30/2021
Q2
3/31/2021
Q1
12/31/2020
Q4
9/30/2020
Q3
6/30/2020
Q2
Revenues 6,7503,000    
Gross profit: 6,7503,000    
Operating expenses(69,209)(17,900)(17,307)(20,767)(22,663)(22,901)(20,752)
Operating loss:(69,209)(11,150)(14,307)(20,767)(22,663)(22,901)(20,752)
Nonoperating expense
(Investment Income, Nonoperating)
   (3)(18)  
Other undisclosed income from continuing operations before equity method investments, income taxes    1,108  
Loss from continuing operations before equity method investments, income taxes:(69,209)(11,150)(14,307)(20,770)(21,573)(22,901)(20,752)
Other undisclosed income from continuing operations before income taxes347      
Loss before gain (loss) on sale of properties:(68,862)(11,150)(14,307)(20,770)(21,573)(22,901)(20,752)
Other undisclosed net income (loss)(348)  375(993)  
Net loss:(69,210)(11,150)(14,307)(20,395)(22,566)(22,901)(20,752)
Other undisclosed net income (loss) attributable to parent (22)(4)  167361
Net loss available to common stockholders, diluted:(69,210)(11,172)(14,311)(20,395)(22,566)(22,734)(20,391)

Comprehensive Income ($ in thousands)

12/31/2021
Q4
9/30/2021
Q3
6/30/2021
Q2
3/31/2021
Q1
12/31/2020
Q4
9/30/2020
Q3
6/30/2020
Q2
Net loss:(69,210)(11,150)(14,307)(20,395)(22,566)(22,901)(20,752)
Comprehensive loss:(69,210)(11,150)(14,307)(20,395)(22,566)(22,901)(20,752)
Other undisclosed comprehensive income (loss), net of tax, attributable to parent (22)(4)(3)(43)96403
Comprehensive loss, net of tax, attributable to parent:(69,210)(11,172)(14,311)(20,398)(22,609)(22,805)(20,349)

Statements sources

The financial statements are based on the company's filings with the The U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: